Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Fisher & Paykel Healthcare Corp Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $11.02 billion
P/E Ratio 23.42
Dividend Yield 2.01%
Shares Outstanding 577.05 million
Earnings per share 0.898
Dividend per share 0.38
Year To Date Return -37.47%
Earnings Yield 4.27%
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
Latest News

Share Gainers

Why BrainChip, Coles, Fisher & Paykel Healthcare, and PolyNovo shares are rising

These ASX shares are rising despite the selloff...

Read more »

high, climbing, record high
Share Gainers

Guess which ASX 200 shares are defying today’s sell-off to climb higher

These ASX 200 shares are bucking the bleakness.

Read more »

asx share price falling lower represented by investor wearing paper bag on head with sad face
Share Fallers

These were the worst performing ASX 200 shares in March

These ASX 200 shares were out of form last month...

Read more »

Share Fallers

Why Evolution, Fisher & Paykel Healthcare, St Barbara, and Zip shares are falling

These ASX shares are falling on Monday...

Read more »

a man clasps his hand to his forehead as he looks down at his phone and grimaces with a pained expression on his face as he watches the IAG share price continue to fall
Share Fallers

These were the worst performing ASX 200 shares last week

These ASX 200 shares were out of form last week...

Read more »

Man holding phone in front of stocks graphic
Share Market News

ASX 200 (ASX:XJO) midday update: Premier’s record dividend, BHP upgraded

The ASX 200 is ending the week in a positive fashion...

Read more »

Red arrow going down on a stock market table which symbolises a falling share price.
Share Fallers

Why Austal, Cettire, Fisher & Paykel Healthcare, and Resimac shares are sinking

These ASX shares are sinking on Wednesday...

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Share Market News

ASX 200 (ASX:XJO) midday update: Block and Zip jump, Fisher & Paykel Healthcare sinks

The ASX 200 is having another positive day...

Read more »

Frequently Asked Questions

Yes. Fisher & Paykel Healthcare has paid twice yearly, unfranked dividends every year since mid-2002, the year following its initial listing on the ASX. The company paid an interim dividend of 11.48 cents per share on 19 December 2019. Fisher & Paykel Healthcare’s final dividend payment of 18.24 cents per share will be paid on 17 July 2020.

Fisher & Paykel Healthcare established a dividend reinvestment plan in 2009 however it has been suspended since May 2019 so is not currently in operation.

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
10 Dec 2009 $0.0429 0.00% Interim 18 Dec 2009
22 Jun 2009 $0.0560 0.00% Final 06 Jul 2009

FPH ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Fisher & Paykel Healthcare Corp Ltd

Fisher & Paykel Healthcare Corp Ltd (FPH) is a global designer and manufacturer of products and systems for use in a range of healthcare services. The company’s products are split into two groups: hospital and homecare.

In the hospital product group, Fisher & Paykel provides a range of humidification products such as ventilators and nasal high flow for adults and infants. Within homecare, Fisher & Paykel is a leading provider of CPAP devices and humidifiers for those who suffer from obstructive sleep apnea.

The overarching Fisher & Paykel company was established in 1934 as an importer of refrigerators and washing machines. The company’s involvement in healthcare began in 1969 when it looked to branch out and benefit from growing manufacturing and electronic expertise.

In 2001, the company split into two separate entities, healthcare and appliances. Today, Fisher & Paykel Healthcare reaches customers in more than 120 countries and its shares are listed on both the ASX and NZX.

FPH Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
13 May 2022 $19.09 $0.64 3.47% 438,471 $18.49 $19.14 $18.44
12 May 2022 $18.45 $-0.76 -3.96% 784,150 $18.80 $19.13 $18.43
11 May 2022 $19.21 $0.02 0.10% 636,255 $18.96 $19.22 $18.82
10 May 2022 $19.19 $-0.03 -0.16% 691,351 $19.10 $19.34 $18.94
09 May 2022 $19.22 $-0.62 -3.13% 603,205 $19.72 $19.85 $19.15
06 May 2022 $19.84 $0.44 2.27% 705,121 $19.18 $19.98 $19.08
05 May 2022 $19.40 $0.24 1.25% 833,555 $19.39 $19.54 $19.25
04 May 2022 $19.16 $-0.08 -0.42% 338,358 $19.53 $19.53 $19.06
03 May 2022 $19.24 $-0.24 -1.23% 427,294 $19.68 $19.84 $19.17
02 May 2022 $19.48 $-0.32 -1.62% 309,115 $19.40 $19.68 $19.23
29 Apr 2022 $19.80 $0.40 2.06% 650,127 $19.51 $19.91 $19.44
28 Apr 2022 $19.40 $-0.30 -1.52% 1,553,843 $19.82 $19.91 $19.30
27 Apr 2022 $19.70 $-0.39 -1.94% 905,029 $19.98 $19.98 $19.62
26 Apr 2022 $20.09 $-0.24 -1.18% 722,741 $20.11 $20.37 $20.03
22 Apr 2022 $20.33 $-0.29 -1.41% 479,250 $20.45 $20.52 $20.22
21 Apr 2022 $20.62 $-0.32 -1.53% 344,893 $21.08 $21.13 $20.51
20 Apr 2022 $20.94 $0.50 2.45% 773,519 $20.65 $21.27 $20.54

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
06 Dec 2021 Lisa McIntyre Buy 4 $142,790
As advised by the company. Trading in NZD$
Purchase of Ordinary Shares
As per announcement on 09/12/2021.
16 Sep 2021 Lewis Gradon Exercise 32 $991,511
Conversion of securities. 91,787 - Performance Share Rights
Trading in $NZD
16 Sep 2021 Lewis Gradon Exercise 100 $3,063,559
Exercise of options. Trading in $NZD
16 Sep 2021 Lewis Gradon Sell 80 $2,497,192
As advised by the company. Sale of ordinary shares
Trading in $NZD
16 Sep 2021 Lewis Gradon Buy 53 $1,619,780
Exercise of options. Trading in $NZD
16 Sep 2021 Lewis Gradon Buy 32 $991,511
Conversion of securities. Trading in $NZD
01 Sep 2021 Lewis Gradon Issued 25 $813,274
Issue of securities. 124,253 - Performance Rights
Trading in $NZD
01 Sep 2021 Lewis Gradon Issued 73 $2,324,593
Issue of options. Trading in $NZD

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Michael Grenfell Daniell Non-Executive Director Nov 2001
Mr Daniell is a member of the Council of the University of Auckland, a director of Cochlear Limited, Tait Limited and the Medical Research Commercialisation Fund, and Chair of the Medical Technologies Centre of Research Excellence. He is a member of Risk Committee.
Mr Lewis George Gradon Chief Executive OfficerManaging Director Apr 2016
Mr Gradon during his 37-year tenure with Fisher & Paykel Healthcare he has held various engineering positions overseeing the development of our range of products as well the development of our manufacturing, quality, intellectual property, supply chain and clinical research functions.
Mr Neville Mitchell Non-Executive Director Nov 2018
Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited between 1995 and 2017. He is non-executive director of Sonic Healthcare, Osprey Medical and Q'Biotics Group, a member of the Australian Board of Taxation, and a director of the South East Sydney Local Health District Board. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission. He is a member of Quality, Safety and Regulatory Committee.
Dr Lisa Margaret McIntyre Non-Executive Director Oct 2021
Dr McIntyre has knowledge in health and technology - with experience in strategy, finance, technology transformation and data analytics. Dr McIntyre is an experienced company director with a portfolio that spans the health care, insurance, technology and e-learning sectors. She is currently a non-executive director of Insurance and Care NSW (a government public financial corporation), HCF Group (a private health insurance company in Australia), The University of Sydney, Studiosity and Nanosonics, and chair of LEK Consulting's ANZ Advisory Board. Prior to her director roles, Dr McIntyre spent 20 years as a senior strategy partner with LEK Consulting. She helped develop the company's US biotechnology advisory practice from three clients in the emerging sector to become the largest biotechnology practice in the US, providing strategic, commercial and operational advice to local and multinational companies in North America, Asia and Australia. She will also serve as a member of the Quality, Safety and Regulatory Committee, effective 1 October 2021 of FPH.
Mr Donal Paul O'Dwyer Non-Executive Director Dec 2012
Mr O'Dwyer is a director of Cochlear Limited, Mesoblast Limited and nib Holdings Limited. From 1996 to 2003, he was with Cordis Cardiology, initially as its president (Europe) and from 2000 to 2003 as its worldwide president. He worked for 12 years with Baxter Healthcare, as a plant manager in Ireland & then president of the Cardiovascular Group, Europe, now Edwards Lifesciences. He is the chairman of Quality, Safety & Regulatory Committee and member of People Committee.
Ms Geraldine Celia McBride Non-Executive Director Aug 2013
Ms McBride has been in the technology industry for 30 years and has global experience. She has held senior executive roles at SAP AG and Dell Inc, and is a former President of SAP North America. She is a director of National Australia Bank and Sky Network Television Ltd, and the founder and CEO of MyWave.
Mr Scott Andrew St John Non-Executive DirectorNon-Executive Chairman Oct 2015
Mr Carter was managing director of Foodstuffs New Zealand Limited for ten years until his retirement in 2010. He is chairman of the board of TR Group and Datacom Group, a director of Vector Limited and ANZ Bank New Zealand Limited, and a trustee of the Maurice Carter Charitable Trust. He is a member of Quality, Safety & Regulatory, People and Risk Committee.
Ms Philippa (Pip) Mary Greenwood Non-Executive Director Jun 2017
Ms Greenwood is a director of Spark New Zealand Limited, Westpac New Zealand Limited and a2 Milk Company Limited, a current trustee of the Auckland Writers Festival and served as a member of the New Zealand Takeovers Panel from 2007 to 2011. She was a partner at Russell McVeagh between 2001 and 2019 and previously served as the firm's Board Chair. She has advised on market transactions. She is the chairman of People Committee.
Mr Marcus James Driller Company SecretaryVice President - Corporate
Marcus James Driller Company SecretaryVice President - Corporate

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Nominees (New Zealand) Limited 84,735,040 14.70%
HSBC Nominees (New Zealand) Limited I 66,978,951 11.62%
Jpmorgan Chase Bank 58,909,933 10.22%
Citibank Nominees (Nz) Ltd 41,810,783 7.25%
HSBC Custody Nominees (Australia) Limited 39,770,963 6.90%
Jpmorgan Nominees Australia Pty Limited 21,751,016 3.77%
Citicorp Nominees Pty Limited 18,666,433 3.24%
Tea Custodians Limited 15,191,575 2.64%
New Zealand Superannuation Fund Nominees Limited 12,416,669 2.15%
National Nominees New Zealand Limited 11,789,542 2.05%
Accident Compensation Corporation 9,617,415 1.67%
BNP Paribas Nominees Nz Limited Bpss40 9,391,635 1.63%
Cogent Nominees Limited 8,845,907 1.53%
Custodial Services Limited 7,542,681 1.31%
BNP Paribas Noms Pty Ltd 6,724,163 1.17%
National Nominees Limited 6,379,451 1.11%
Premier Nominees Limited 6,339,895 1.10%
FNZ Custodians Limited 6,193,852 1.07%
Custodial Services Limited I 5,953,253 1.03%
Jbwere (Nz) Nominees Limited 4,596,927 0.80%